Form 4: GE HealthCare CTO Awarded Equity, Options
Insider Transaction Report
GE HealthCare Technologies Inc.'s Chief Technology Officer, Taha Kass-Hout, received awards of restricted stock units and employee stock options.
Summary
- Taha Kass-Hout, Chief Technology Officer of GE HealthCare Technologies Inc., was awarded 13,254 restricted stock units (RSUs) of common stock.
- These RSUs represent the right to receive one share of common stock per unit at settlement, with a vesting schedule of 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029.
- Kass-Hout also received an award of 34,847 employee stock options with an exercise price of $80.16 per share.
- The stock options will become exercisable according to the same vesting schedule as the RSUs: 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029, and expire on March 2, 2036.
- Following these transactions, Kass-Hout beneficially owns 92,909 shares of common stock directly and 34,847 derivative securities (employee stock options) directly.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices aimed at retention and alignment of interests, without indicating any significant operational or financial shifts.
Positives
- The equity awards align the Chief Technology Officer's interests with those of shareholders, incentivizing long-term performance and retention.
- The awards represent a significant component of executive compensation, reflecting confidence in the executive's continued contribution to the company's strategic objectives.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that equity awards, such as restricted stock units and stock options, are standard components of executive compensation packages across the healthcare technology industry. These awards are designed to incentivize long-term performance, align management interests with shareholder value, and retain key talent in a competitive market.
Comparison to Industry Standards
- Executive compensation structures in the healthcare technology sector frequently include a mix of base salary, cash bonuses, and long-term incentive awards like RSUs and stock options, similar to this filing.
- The vesting schedules, typically over several years, are common practice to ensure executive retention and sustained performance, comparable to companies like Medtronic or Siemens Healthineers.
Stakeholder Impact
- Shareholders: Potential minor dilution from the issuance of new shares upon vesting/exercise, but also benefit from incentivized executive performance and retention.
- Employees: May signal stability in executive leadership and a commitment to long-term incentive programs.
Next Steps
- The restricted stock units will vest in three tranches on September 2, 2027, September 2, 2028, and September 2, 2029.
- The employee stock options will become exercisable in three tranches on September 2, 2027, September 2, 2028, and September 2, 2029, and will expire on March 2, 2036.
Key Dates
| Date | Description |
|---|---|
| 03/02/2026 | Date of earliest transaction for the award of restricted stock units and employee stock options. |
| 03/04/2026 | Date the Form 4 was signed by the attorney-in-fact. |
| 09/02/2027 | First vesting date for 33% of restricted stock units and exercisability date for 33% of employee stock options. |
| 09/02/2028 | Second vesting date for 33% of restricted stock units and exercisability date for 33% of employee stock options. |
| 09/02/2029 | Final vesting date for 34% of restricted stock units and exercisability date for 34% of employee stock options. |
| 03/02/2036 | Expiration date for the employee stock options. |
Keywords
GE HealthCare Technologies, GEHC, Taha Kass-Hout, Chief Technology Officer, Restricted Stock Units, RSUs, Employee Stock Options, Equity Award, Insider Transaction, Executive Compensation, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.